![Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-28410-9/MediaObjects/41467_2022_28410_Fig1_HTML.png)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
![Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram](https://www.researchgate.net/publication/331028577/figure/fig4/AS:941421343305740@1601463747636/Percentage-Progression-free-survival-and-overall-survival-on-treatment-a-Median-PFS-is.png)
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
![Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-01042-y/MediaObjects/41375_2020_1042_Fig2_HTML.png)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
![Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram](https://www.researchgate.net/publication/339177178/figure/fig4/AS:857392841490434@1581429791443/Median-overall-survival-OS-and-progression-free-survival-PFS-in-a-population-based.png)
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
![a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram](https://www.researchgate.net/publication/330793879/figure/fig1/AS:721488437051394@1549027656209/a-Median-progression-free-survival-PFS-to-second-line-SL-therapy-b-The-median.png)
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
![Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small](https://www.mdpi.com/diagnostics/diagnostics-12-00423/article_deploy/html/images/diagnostics-12-00423-g001.png)
Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small
![Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram](https://www.researchgate.net/publication/343894797/figure/fig1/AS:938411976298498@1600746258580/Kaplan-Meier-analysis-of-a-progression-free-survival-PFS-and-b-overall-survival.png)
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
![Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram](https://www.researchgate.net/publication/273896949/figure/fig2/AS:613943508746271@1523386947939/Progression-free-survival-median-PFs-206-days-95-ci-153-259-and-overall-survival.png)
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611 OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611](https://library.ehaweb.org/image/abstracts/eha_2021/EHA-2476.jpg)
OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2407-14-18/MediaObjects/12885_2013_Article_4261_Fig1_HTML.jpg)
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
![Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram](https://www.researchgate.net/publication/331026250/figure/fig2/AS:734407153418240@1552107718315/Kaplan-Meier-plot-of-progression-free-survival-Median-progression-free-survival-PFS-for.jpg)
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
![NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd](https://pbs.twimg.com/media/E_kfruMVEAMovt5.jpg)
NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
![Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram](https://www.researchgate.net/profile/Shuichi-Hironaka/publication/238690897/figure/fig1/AS:298792017514512@1448248976976/Progression-free-survival-PFS-and-overall-survival-OS-time-Median-PFS-mPFS-was-105.png)
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)